Day One Biopharmaceuticals, Inc. DAWN
We take great care to ensure that the data presented and summarized in this overview for Day One Biopharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DAWN
View all-
Atlas Venture Life Science Advisors, LLC6.43MShares$104 Million13.29% of portfolio
-
Black Rock Inc. New York, NY5.03MShares$81.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$77.2 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.81MShares$61.6 Million0.02% of portfolio
-
State Street Corp Boston, MA2.89MShares$46.8 Million0.0% of portfolio
-
Viking Global Investors LP2.56MShares$41.4 Million0.16% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.38MShares$38.4 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.3MShares$37.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT2.17MShares$35.1 Million1.16% of portfolio
-
Goldman Sachs Group Inc New York, NY2.14MShares$34.6 Million0.01% of portfolio
Latest Institutional Activity in DAWN
Top Purchases
Top Sells
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Insider Transactions at DAWN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,873
-1.19%
|
$125,968
$16.08 P/Share
|
|
May 16
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
2,675
-1.18%
|
$42,800
$16.08 P/Share
|
|
May 16
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
2,267
-0.19%
|
$36,272
$16.08 P/Share
|
|
May 16
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,253
-13.02%
|
$52,048
$16.08 P/Share
|
|
May 15
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,999
+1.0%
|
-
|
|
May 15
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
10,250
+1.49%
|
-
|
|
May 15
2024
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,686
+0.25%
|
-
|
|
May 15
2024
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
8,399
+11.2%
|
-
|
|
May 10
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.85%
|
$160,000
$16.37 P/Share
|
|
May 03
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,154
-1.4%
|
$155,618
$17.85 P/Share
|
|
May 03
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
8,078
-3.58%
|
$137,326
$17.85 P/Share
|
|
May 02
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6
-0.0%
|
$102
$17.94 P/Share
|
|
May 02
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
200
-0.09%
|
$3,400
$17.9 P/Share
|
|
May 01
2024
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
70,051
-9.7%
|
$1,190,867
$17.88 P/Share
|
|
May 01
2024
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
52,183
-18.79%
|
$887,111
$17.89 P/Share
|
|
Apr 18
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$160,000
$16.02 P/Share
|
|
Mar 25
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$160,000
$16.01 P/Share
|
|
Mar 11
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
30,000
-2.45%
|
$450,000
$15.24 P/Share
|
|
Feb 27
2024
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
20,000
-1.61%
|
$320,000
$16.11 P/Share
|
|
Feb 16
2024
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
3,242
-16.35%
|
$48,630
$15.25 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 137K shares |
|---|---|
| Bona fide gift | 570K shares |
| Other acquisition or disposition | 240K shares |
| Open market or private purchase | 2.24M shares |
| Open market or private sale | 267K shares |
|---|---|
| Bona fide gift | 570K shares |
| Other acquisition or disposition | 240K shares |